Lenti MV, Dolby V, Clark T, Hall V, et al. A propensity score-matched, real-world comparison of ustekinumab vs vedolizumab as a second-line treatment for Crohn's disease. The Cross Pennine study II. Aliment Pharmacol Ther 2022;55:856-866.
PMID: 34935160